Shots:

• The P-IIb (QUASAR) induction study evaluates Tremfya (200/400mg, IV) vs PBO in 313 patients with UC with inadequate response/intolerance to conventional therapies or advanced therapies
• The results showed that patients achieved clinical response @12wk. (61.4%/60.7% vs 27.6%), clinical remission rates (25.7%/25.2% vs 9.5%), symptomatic remission rates (50.5%/47.7% vs 20%), endoscopic improvement rates (30.7%/30.8% vs 12.4%), histo-endoscopic mucosal improvement (19.8/27.1% vs 8.6%), endoscopic normalization rates (17.8%/14% vs 6.7%) & safety data were consistent with safety profile for Tremfya
• Tremfya is approved in the US, Canada, Japan, EU & other countries globally for PsO & active PsA

 Ref: PR Newswire | Image: Medical Dialogues